ClinicalTrials.gg
Active, not recruitingNCT07264205Updated Oct 30, 2026

RT-310 Safety and Feasibility BPH Study

A Phase 1/2 interventional study of RT-310 in BPH (Benign Prostatic Hyperplasia), sponsored by Resurge Therapeutics Inc.. Active, not recruiting at 1 site in Dominican Republic. Open to male participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Resurge Therapeutics Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Mar 2025, registered Nov 2025).
Updated Oct 30, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
50 Years to 80 Years
Sex
Male
01

Study summary

RT-310, is intended to deliver drug locally to the prostate gland for the management of prostate disease, while minimizing systemic exposure and its associated side-effects. The objectives of the study are to assess whether RT-310 is safe and feasible for the participant population.

02

Conditions studied

  • BPH (Benign Prostatic Hyperplasia)

Browse trials for

03

In context

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

This study's planned enrollment of 20 is below the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.

Browse Prostatic Hyperplasia studies →

Lead sponsor

Resurge Therapeutics Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male gender
  • Diagnosis of symptomatic BPH
  • Age ≥ 50 years up to 80 years
  • International Prostate Symptom Score (IPSS) ≥ 13
  • Peak urine flow rate ≥ 5mL/sec and ≤ 12 ml/sec, voided volume ≥ 100 ml
  • Prostate volume 30 to 80 cc per ultrasound
  • Post void residual (PVR) urine ≤ 250 ml
  • Inadequate response and/or refusal of medical therapy for LUTS

Exclusion criteria

Exclusion Criteria:

  • Unable or unwilling to sign the form (ICF) and/or comply with the study follow-up requirements
  • Current urinary retention requiring catheterization
  • Unwilling to abstain from unprotected sexual intercourse for 3 months
  • Unwilling to abstain from any child conceiving activities for 6 months
  • Have an obstructive or protruding median lobe of the prostate
  • High bladder neck determined by Investigator
  • Active urinary tract infection at time of treatment
  • Previous BPH surgical procedure or implants, urethral stricture, Any prior minimally invasive intervention (e.g. TUNA, Balloon, Microwave, Rezūm, UroLift) or surgical intervention of the prostate
  • Previous pelvic surgery or irradiation
  • History of neurogenic or atonic bladder
  • Stress urinary incontinence, mixed or urge incontinence
  • of the prostate within the past 6 weeks
  • estimated to be less than 1 year
  • History of prostate or bladder cancer, confirmed or suspected of prostate or bladder
  • History of compromised renal function or upper urinary tract disease
  • Known coagulopathies or participant on anticoagulants or antiplatelets other than aspirin ≤ 100 mg (unless antiplatelets are withheld minimum 3 days prior to procedure)
  • Use of the following medications pre-screening:

Within 6 months of baseline assessment, unless documented on stable dose for ≥ 12 months: 5-alpha-reductase inhibitors (e.g. dutasteride, Avodart, finasteride, Proscar, Propecia) Within 4 months of baseline assessment: estrogen, any drug producing androgen suppression, or anabolic steroids Within 2 weeks of baseline assessment: alpha-blockers, gonadotropin- releasing hormonal analogs, anticholinergics or cholinergic medication or phenylephrine, pseudoephedrine, diphenhydramine or imipramine medications Within 1 week of baseline assessment, unless documented on stable dose for ≥ 6 months: beta blockers, antidepressants, anticonvulsants, and antispasmodics

  • Cystolithiasis within the prior 3 months
  • History of co-morbidities that would affect having an elective urological procedure including prostatitis, conditions that preclude the RT-310.
  • Other co-morbidities that could impact the study results such as:

Severe cardiac arrhythmias uncontrolled by medications or pacemaker Congestive heart failure (NYHA) III or IV History of uncontrolled diabetes mellitus Significant respiratory disease in which hospitalization may be required

  • Known (i.e. AIDS, post-transplant, undergoing chemotherapy)
  • Currently enrolled in any other clinical research trial that has not completed the primary endpoint.
  • No more than two documented active urinary tract infections (UTI) by culture or bacterial prostatitis within last year documented by culture (UTI is defined as >100,000 colonies per ml urine from midstream clean catch or catheterization specimen)
  • Current gross hematuria and/or visible hematuria with participant urine sample without known contributing factor
  • Presence of a penile implant or stent(s) in the urethra or prostate
  • PSA > 10 ng/ml unless prostate cancer is ruled out by biopsy. If PSA is > 4 ng/ml and ≤ 10 ng/ml, prostate cancer must be ruled out to the satisfaction of the investigator via additional tests including digital rectal exam (DRE) and/or biopsy
  • Active or history of epididymitis within the past 3 months
  • Sensitivity to RT-310
  • Parkinson's disease or other neurologic disease that may impact bladder function such as stroke, , multiple sclerosis
  • Active infection including prostatitis
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    RT-310

    RT-310

    Combination Product: RT-310

Interventions

  • Combination productRT-310

    RT-310

06

What researchers measure

Primary outcomes

  1. Safety Endpoint

    Absence of unanticipated adverse events (UAEs) not listed in the protocol or Adverse Events (AEs) that meet the protocol definition of Serious Adverse Events (SAEs)

    Time frame: Baseline to Day 180

Secondary outcomes

  1. Change in IPSS

    International Prostate Symptom Score (IPSS)

    Time frame: Baseline to Day 180

  2. Uroflowmetry (Qmax)

    Peak Urinary Flowrate (Qmax)

    Time frame: Baseline to Day 180

07

Study locations

1 site
  • Research Site
    Santo Domingo, Dominican Republic
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2025 to primary completion in Feb 2026, 11 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Mar 2026 → Feb 2026 and completion Jun 2026 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 4, 2025
StartActual
Mar 13, 2025
Primary completionActual
Feb 26, 2026was Mar 2026
CompletionEst.
Aug 2027was Jun 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 2026→Feb 26, 2026 (actual)
Oct 30, 2026
Study completion
Jun 2026→Aug 2027
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Primary completion Mar 2026→Feb 26, 2026 (now actual)
    Study completion Jun 2026→Aug 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07264205
Lead sponsor
Resurge Therapeutics Inc.
Responsible party
Sponsor
First posted
Dec 4, 2025
Start date
Mar 13, 2025
Primary completion
Feb 26, 2026
Completion
Aug 2027 (estimated)
Last update
Oct 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RT-310

Start the discussion